Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Dermatologic 1CNS 1

Conditions

Neoplasms 1Melanoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Brain Diseases 1

Interventions

pembrolizumab 90Blood Specimen Collection 41Cyclophosphamide 37Bevacizumab 36Nivolumab 34Standard of Care 32Carboplatin 32Surveys and Questionnaires 29Paclitaxel 27atezolizumab 25Exercise 25Pemetrexed 24Cisplatin 24Gemcitabine 23Fluorouracil 22Radiotherapy 20Leucovorin 20Dexamethasone 20Oxaliplatin 18Docetaxel 18Rituximab 16Irinotecan 16Cetuximab 16Drug Therapy 15Doxorubicin 15dostarlimab 14Biopsy 14130-nm albumin-bound paclitaxel 14fludarabine 13Prednisone 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × PF-07284890 × 1 year × Clear all
NCT04543188 2025-10-23

A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

Pfizer

Phase 1 Terminated
65 enrolled 52 charts
CNSDermatologicThoracic

Brain Diseases, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡